[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 4 sources · 20 days · First seen · Last updated

South Korean healthcare and biotech KOSDAQ listings

Overview

Multiple South Korean companies in the healthcare and biotechnology sectors have initiated processes to list on the KOSDAQ exchange.

Baropharm, a pharmacy integration platform, has submitted a registration statement to the Financial Services Commission. The company aims to offer between 29.2 billion and 36 billion KRW in shares to fund upgrades to its AI, data, and cloud infrastructure, as well as to support global expansion and pharmaceutical production.

NEX-I, a biotechnology firm specializing in immunotherapy resistance, has also filed for a KOSDAQ listing following preliminary approval from the Korea Exchange. The company intends to raise between 52.5 billion and 65 billion KRW to accelerate clinical development for its NXI-201 candidate and expand research into next-generation antibody-drug conjugates.

Entities

Korea Exchange · Ono Pharmaceutical · Kyung-wan Yoon · Financial Services Commission · Kim Seul-gi

Timeline

  1. [BUSINESS] 4 sources
    NEX-I files for KOSDAQ listing to fund immunotherapy drug development

    Biotech firm NEX-I has filed for a KOSDAQ listing, aiming to raise up to 65 billion KRW to advance its immunotherapy and antibody-drug conjugate pipelines.

  2. [BUSINESS] 2 sources
    Baropharm files for KOSDAQ listing to expand healthcare platform

    Pharmacy platform Baropharm has filed for a KOSDAQ listing, aiming to raise up to 36 billion KRW to expand its AI-driven healthcare platform and global brand presence.

Sources

biotimes.co.kr · bosa.co.kr · newstomato.com · thebionews.net